GCM
AVIR icon

Graham Capital Management’s Atea Pharmaceuticals AVIR Stock Holding History

Graham Capital Management’s Portfolio AVIR Stock Details AVIR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$75.1K Buy
+16,145
New +$80.3K ﹤0.01% 1179
2026
Q1 		– Sell
-12,678
Closed -$45.3K – 1166
2025
Q4 		$45.3K Sell
12,678
-57,312
-82% -$182K ﹤0.01% 1177
2025
Q3 		$203K Buy
69,990
+45,166
+182% +$154K ﹤0.01% 1044
2025
Q2 		$89.4K Buy
24,824
+8,122
+49% +$24.2K ﹤0.01% 1216
2025
Q1 		$49.9K Buy
16,702
+4,191
+33% +$13.1K ﹤0.01% 1232
2024
Q4 		$41.9K Buy
+12,511
New +$41.6K ﹤0.01% 1184
2024
Q1 		– Sell
-11,387
Closed -$34.7K – 1057
2023
Q4 		$34.7K Buy
+11,387
New +$34.5K ﹤0.01% 949
2023
Q3 		– Sell
-10,113
Closed -$37.8K – 1010
2023
Q2 		$37.8K Buy
+10,113
New +$37.9K ﹤0.01% 923
2022
Q4 		– Sell
-149,973
Closed -$853K – 1045
2022
Q3 		$853K Buy
149,973
+128,382
+595% +$983K 0.03% 549
2022
Q2 		$153K Sell
21,591
-54,226
-72% -$370K 0.01% 941
2022
Q1 		$547K Buy
75,817
+42,396
+127% +$288K 0.02% 520
2021
Q4 		$298K Buy
+33,421
New +$521K 0.01% 325

Other funds holding AVIR

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
BCM
BML Capital Management Zionsville, Indiana $176M AUM 123.21% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $2.2B AUM 156.35% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.68B AUM 126.09% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Graham Capital Management's AVIR Position: Q2 2026 in Review

Graham Capital Management opened a new position in Atea Pharmaceuticals (AVIR) in Q2 2026: 16,145 shares worth $75.1K. The stake represents ﹤0.01% of the portfolio and ranks #1179 among its holdings. This is a return to the name: Graham Capital Management previously reported a position in AVIR as recently as Q4 2025.

Graham Capital Management first reported a position in AVIR in Q4 2021 and has held it in 12 quarters since. The position peaked at $853K in Q3 2022. 124 funds tracked by Wall St. Rank hold AVIR as of Q2 2026.

  • Graham Capital Management held 16,145 shares of Atea Pharmaceuticals worth $75.1K as of Q2 2026.
  • Atea Pharmaceuticals was a new Graham Capital Management position in Q2 2026.
  • Atea Pharmaceuticals made up ﹤0.01% of Graham Capital Management's portfolio in Q2 2026, its #1179 holding.
  • Graham Capital Management first reported a position in Atea Pharmaceuticals in Q4 2021 and has held it in 12 quarters since.
  • Graham Capital Management's Atea Pharmaceuticals position peaked at $853K in Q3 2022.
  • 124 funds tracked by Wall St. Rank held Atea Pharmaceuticals as of Q2 2026.

Based on Graham Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.